The Neolpharma Group is firmly committed to the development of research in Mexico, which is why it has combined efforts with various educational and health entities to improve therapies for major chronic diseases affecting the population, among which we can mention:
The incursion into the oncology area through Transkrip®; a drug based on epigenetic therapy that increases the survival rate in patients with cervical, ovarian, breast and other kinds of cancers.
A product with antiepileptic indications but which has shown to protect memory and hearing.
A neuroprotector established as a prominent treatment for stroke.
The development of liquid dosage forms to facilitate delivery of active ingredients to special populations who have difficulty in swallowing.
The pharmaceutical development and clinical research in the various phases of a drug that can improve the quality of life of patients with hearing impairments, among others.
The research by the Neolpharma Group is supported by institutions with national and international recognition such as the National Institute of Neurology and Neurosurgery, Institute of Biomedical Research of the UNAM (Mexican Autonomous University), the National Cancer Institute, the Children's Hospital of Mexico and the National Rehabilitation Institute.
Additionally, the group has links with various institutions such as General Hospital, Hospital Juarez, the Mexican Social Security Institute and the ISSSTE (Government Workers' Social Security and Services Institute) for the development of various clinical protocols. It is noteworthy that in the education sector the Neolpharma Group is engaged, together with the National Autonomous University of Mexico (FES-Zaragoza), in the task of improving the academic and labor perception of physicians interested in the pharmaceutical area.